| The recommended dosage for the Phase II study was 350 mg/m2/day in combination with 800 mg of sorafenib daily. |
| The disease control rate was 75% in this Phase I study. |
| Combination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential of an option for advanced HCC. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.